A Phase 3 interventional study of Abatacept and placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 89 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-16.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 5th largest by enrollment, is one of 4 that started in 2005, is one of 26 in phase 3, and was the 7th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,052 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2005, is one of 22 in phase 3, and was the 7th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
abatacept 10 mg/kg intravenous (IV) + methotrexate
Drug: Abatacept · Drug: methotrexate
placebo IV + methotrexate
Drug: Abatacept · Drug: placebo · Drug: methotrexate
abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12
Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1 = high disease activity; \<=3.2 = low disease activity; \<2.6 = remission.
Time frame: Month 12
Mean Change From Baseline in Radiographic Total Score to Month 12
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
Time frame: Baseline, Month 12
Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label Period
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Number of Participants With Serious Adverse Events Reported During the Open-Label Period
SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Number of Participants With SAEs With an Outcome of Death During the Open-label Period
Any untoward medical occurrence (SAE) that resulted in death
Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Incidence Rates of Autoimmune Disorders in ABA-Treated Participants
The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).
Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants
The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants
The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
Time frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period
There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study.
Time frame: Open-Label Period (Month 12 to Month 24)
Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period
Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) \>2x upper limit of normal (ULN) or if pretreatment (PRE-RX) \>ULN then \>3x PRE-RX; aspartate aminotransferase (AST) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; alanine aminotransferase (ALT) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; g-glutamyl transferase (GGT)\>2x ULN or if PRE-RX \>ULN then \>3x PRE-RX; total bilirubin \>2x ULN or if PRE-RX \>ULN then \>4x PRE-RX; blood urea nitrogen \>2x PRE-RX; creatinine \>1.5x PRE-RX.
Time frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label Period
Marked abnormalities in hemoglobin \>3 g/dL decrease from PRE-RX; hematocrit \<0.75x PRE-RX; erythrocytes \<0.75x PRE-RX; platelet count \<0.67x lower limit of normal (LLN) or \>1.5x ULN or if PRE-RX \<LLN then \<0.5x PRE-RX and \<100,000/mm3; leukocytes \<0.75x LLN or \>1.25x ULN or if PRE-RX \<LLN then \<0.8x PRE-RX or \>ULN if PRE-RX \>ULN then \>1.2x PRE-RX or \<LLN; neutrophils if value \<1.00 x10\^3 c/uL; lymphocytes if value \<.750 x10\^3 c/uL or if value \>7.50 x10\^3 c/uL; monocytes if value \>2000/MM3; basophils if value \>400/mm3; eosinophils if value \>.750 x10\^3 c/uL
Time frame: Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12
ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value \[ie, CRP\].
Time frame: Month 12
Number of Participants With Major Clinical Response (MCR) at Month 12
MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value \[ie, CRP\]).
Time frame: Month 12
Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12
DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value.
Time frame: Baseline, Month 12
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12
Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.
Time frame: Month 12
Adjusted Mean Change in Short Form 36 (SF-36) From Baseline to Month 12
The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value.
Time frame: Baseline, Month 12
Mean Change From Baseline in Radiographic Erosion and Joint Space Narrowing (JSN) Scores to Month 12
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value
Time frame: Baseline, Month 12
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses in the Double-blind Period as Analyzed by Enzyme-linked-immunosorbent Serologic Assay (ELISA)
Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).
Time frame: includes data up to approximately 85 days past the last dose of the double-blind period or start of the open-label period, whichever occurred first.
Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA
Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).
Time frame: Includes open-label data up to approximately 85 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24
Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.
Time frame: Baseline, Month 24
Mean Change From Baseline in Radiographic Total, Erosion and JSN Scores to Month 24
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value.
Time frame: Baseline, Month 24
Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) From Baseline at Month 24
Participants with no radiographic progression (defined as change in score \<=0 or \<=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
Time frame: Baseline, Month 24
Number of Participants Without Radiographic Progression (as Measured by in Erosion Scores, JSN Scores, and Total Scores) at Month 24 in Participants Without Progression at Month 12
Participants with no radiographic progression ((defined as change in score \<=0 or \<=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
Time frame: Month 12, Month 24
Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score)
Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
Time frame: Baseline, Month 12, Month 24
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Reported During the Double-blind Period
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.
Number of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During the Double-blind Period
Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria
Time frame: Includes data up to 56 days post the last dose in the double-blind period or start of the open-label period, whichever occurred first.
| Milestone | Abatacept (ABA) + Methotrexate (MTX) (Double-Blind) | Placebo (PLA) + Methotrexate (MTX) (Double-Blind) | ABA + MTX (Open-Label) |
|---|---|---|---|
| Started | 256 | 255 | 0 |
| Treated | 256 | 253 | 0 |
| Completed | 232 | 227 | 0 |
| Not completed | 24 | 28 | 0 |
| Withdrew: Adverse event | 9 | 11 | 0 |
| Withdrew: Death | 2 | 2 | 0 |
| Withdrew: Lack of efficacy | 0 | 8 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 0 |
| Withdrew: Subject no longer meets study criteria | 1 | 0 | 0 |
| Withdrew: Withdrawal of consent | 7 | 3 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Methotrexate discontinued | 0 | 1 | 0 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 |
| Milestone | Abatacept (ABA) + Methotrexate (MTX) (Double-Blind) | Placebo (PLA) + Methotrexate (MTX) (Double-Blind) | ABA + MTX (Open-Label) |
|---|---|---|---|
| Started | 0 | 0 | 459 |
| Completed | 0 | 0 | 433 |
| Not completed | 0 | 0 | 26 |
| Withdrew: Adverse event | 0 | 0 | 11 |
| Withdrew: Death | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Poor/non-compliance | 0 | 0 | 1 |
| Withdrew: Withdrawal of consent | 0 | 0 | 4 |
ACR 50 response was defined as a 50% improvement from baseline to Month 12 in tender and swollen joint counts and 50% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function), and 1 acute phase reactant value \[ie, CRP\].
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Number of Participants With American College of Rheumatology (ACR) 50 Response at Month 12 | 147 | 107 |
MCR was defined as 6 months of consecutive ACR 70 response at Month 12. ACR 70, the American College of Rheumatology (ACR) definition of 70% improvement was based on a 70% improvement (compared to baseline values) in tender and swollen joint counts and 70% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function, and 1 acute phase reactant value \[ie, CRP\]).
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Number of Participants With Major Clinical Response (MCR) at Month 12 | 70 | 30 |
DAS 28-CRP is a continuous variable that is a composite of 4 variables: the number of tender joints out of 28 joints, the number of swollen joints out of 28 joints, CRP in milligrams/Liter (mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 to 10, indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission. Change from Baseline=Post-baseline - Baseline value; Adjusted for baseline value.
| units in a scale | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Adjusted Mean Change From Baseline in DAS-28-CRP Score to Month 12 | -3.22 ± 0.09 | -2.49 ± 0.09 |
Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 12 | 184 | 157 |
The SF-36 covers 8 health dimensions: 4 physical subscales (physical function, role-physical, bodily pain, and general health) and 4 mental subscales (vitality, social function, role-emotional, and mental health). The scores range from 0 to 100, with a higher score indicating better quality of life. Two summary scores (physical and mental component summaries) were produced taking a weighted linear combination of the 8 individual subscales. Change from Baseline=Post-baseline - Baseline value; adjusted for baseline value.
| units on a scale | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Physical Component Summary (PCS) Score | 11.68 ± 0.62 | 9.18 ± 0.63 |
| Mental Component Summary (MCS) Score | 8.15 ± 0.64 | 6.34 ± 0.64 |
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The erosion score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). The joint space narrowing score range is 0 (no radiographic damage) to 145 (worst possible radiographic damage). Higher scores indicated more damage. Change from baseline = Post-baseline - Baseline value
| units on a scale | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Baseline Mean Erosion Score | 5.48 ± 6.15 | 4.81 ± 5.46 |
| Mean Change from Baseline in Erosion Score | 0.50 ± 1.39 | 0.89 ± 2.24 |
| Baseline Mean JSN Score | 2.03 ± 3.99 | 1.86 ± 3.95 |
| Mean Change from Baseline in JSN Score | 0.13 ± 0.53 | 0.17 ± 0.54 |
Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).
| Participants | ABA+ MTX On-treatment | ABA + MTX Post-discontinuation |
|---|---|---|
| Anti-abatacept Responses | 3 | 0 |
| Anti-CTLA4-T Responses | 1 | 1 |
Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumatoid arthritis. A DAS28 \>5.1 = high disease activity; \<=3.2 = low disease activity; \<2.6 = remission.
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 | 106 | 59 |
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and joint space narrowing (JSN). The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
| units on a scale | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Baseline Mean | 7.50 ± 9.52 | 6.67 ± 8.71 |
| Mean Change from Baseline | 0.63 ± 1.74 | 1.06 ± 2.45 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| participants | ABA + MTX (Open-Label) |
|---|---|
| AEs | 345 |
| Related AEs | 128 |
| SAEs | 29 |
| Related SAEs | 10 |
| Discontinuations due to AEs | 11 |
| Discontinuations due to SAEs | 4 |
| Deaths | 2 |
SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| participants | ABA + MTX (Open Label) |
|---|---|
| Any SAE | 29 |
| Infections and infestations | 8 |
| Gastrointestinal disorders | 4 |
| Nervous system disorders | 4 |
| Cardiac disorders | 3 |
| Hepatobiliary disorders | 3 |
| Eye disorders | 2 |
| Musculoskeletal and connective tissue disorders | 2 |
| Vascular disorders | 2 |
| Immune System Disorders | 1 |
| Injury, Poisoning, and Procedural Complications | 1 |
| Investigations | 1 |
| Metabolism and Nutrition Disorders | 1 |
| Renal and Urinary Disorders | 1 |
| Respiratory, Thoracic, and Mediastinal Disorders | 1 |
Serum samples were analyzed by ELISA to detect antibodies against the whole molecule (both CTLA4 and Ig \[anti-abatacept antibody\]) or solely to CTLA4 (anti-CTLA4-T antibody). Reported as titer, the reciprocal of the sample dilution which yielded a signal equivalent to the statistically set cut point for the assay. For the anti-abatacept assay, minimum required dilution is 400-fold, therefore seronegative samples are those \< lowest reportable titer (\<400). For the anti-CTLA4-T assay, minimum required dilution is 25-fold, therefore seronegative samples are those \< lowest reportable titer (\<25).
| participants | Anti-Abatacept Antibody Response | Anti-CTLA4-T Antibody Response |
|---|---|---|
| Number of Participants With Anti-abatacept or Anti-CTLA4-T Responses During the Open-Label Period (From Month 12 to Month 24) as Analyzed by ELISA | 13 | 16 |
Physical function was evaluated using the HAQ-disability index (HAQ-DI), a questionnaire with 20 questions assessing function in 8 domains: dressing, arising, eating, walking, hygiene, reach, grip, and common activities. The questions are evaluated on a 4-point scale: 0 = without any difficulty; 1 = with some difficulty; 2 = with much difficulty; 3 = unable to do. The 8 category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). Higher scores indicate greater dysfunction. HAQ response=improvement of at least 0.3 units from baseline.
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Number of Participants With Health Assessment Questionnaire (HAQ) Response at Month 24 | 189 | 178 |
To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage. Change from baseline = Postbaseline - baseline value.
| units on a scale | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Erosion Score Baseline Mean | 5.91 ± 6.48 | 5.49 ± 5.85 |
| Erosion Score Mean Change from Baseline | 0.59 ± 2.31 | 1.40 ± 3.08 |
| JSN Score Baseline Mean | 1.83 ± 3.82 | 1.75 ± 3.92 |
| JSN Score Mean Change from Baseline | 0.25 ± 1.03 | 0.34 ± 0.99 |
| Total Score Baseline Mean | 7.73 ± 9.50 | 7.24 ± 8.89 |
| Total Score Mean Change from Baseline | 0.84 ± 3.22 | 1.75 ± 3.59 |
Any untoward medical occurrence (SAE) that resulted in death
| participants | ABA + MTX (Open-Label) |
|---|---|
| Pneumonia | 1 |
| Pneumonia/septic shock | 1 |
The incidence rates of autoimmune disorders are defined as the (number of patients experiencing the event/exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
| Number of participants/100 patient-years | ABA + MTX (Double-Blind) | ABA + MTX (Open-Label) |
|---|---|---|
| Incidence Rates of Autoimmune Disorders in ABA-Treated Participants | 2.47 | 1.30 |
The incidence rates of infections and infestations are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
| Number of patients/100 patient-years | ABA + MTX (Double-Blind) | ABA + MTX (Open-Label) |
|---|---|---|
| Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated Participants | 78.37 | 66.68 |
The incidence rates of malignant neoplasms are defined as the (number of patients experiencing the event /exposure within the period)\*100 and are expressed in 100 person-years. Subjects experiencing the event had their exposure censored at the time of the 1st event.
| number of patients/100 patient-years | ABA + MTX (Double-Blind) | ABA + MTX (Open-Label) |
|---|---|---|
| Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated Participants | 0.81 | 0 |
There were 107 Prespecified, acute-infusional SAEs (occurring within 1 hour after the start of study drug infusion) pre-specified in the protocol; anaphylactic shock was the only one occuring in this study.
| Participants | ABA + MTX (Open-label) |
|---|---|
| Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label Period | 1 |
Number of subjects with high liver function and kinedy tests: alkaline phosphatase (ALP) \>2x upper limit of normal (ULN) or if pretreatment (PRE-RX) \>ULN then \>3x PRE-RX; aspartate aminotransferase (AST) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; alanine aminotransferase (ALT) \>3x ULN or if PRE-RX \>ULN then \>4x PRE-RX; g-glutamyl transferase (GGT)\>2x ULN or if PRE-RX \>ULN then \>3x PRE-RX; total bilirubin \>2x ULN or if PRE-RX \>ULN then \>4x PRE-RX; blood urea nitrogen \>2x PRE-RX; creatinine \>1.5x PRE-RX.
| participants | ABA + MTX (Open-Label) |
|---|---|
| ALP (n=459) | 2 |
| AST (n=459) | 10 |
| ALT (n=459) | 24 |
| GGT (n=459) | 15 |
| Total Bilirubin (n=459) | 0 |
| Blood Urea Nitrogen (n=459) | 13 |
| Creatinine (n=457) | 81 |
Marked abnormalities in hemoglobin \>3 g/dL decrease from PRE-RX; hematocrit \<0.75x PRE-RX; erythrocytes \<0.75x PRE-RX; platelet count \<0.67x lower limit of normal (LLN) or \>1.5x ULN or if PRE-RX \<LLN then \<0.5x PRE-RX and \<100,000/mm3; leukocytes \<0.75x LLN or \>1.25x ULN or if PRE-RX \<LLN then \<0.8x PRE-RX or \>ULN if PRE-RX \>ULN then \>1.2x PRE-RX or \<LLN; neutrophils if value \<1.00 x10\^3 c/uL; lymphocytes if value \<.750 x10\^3 c/uL or if value \>7.50 x10\^3 c/uL; monocytes if value \>2000/MM3; basophils if value \>400/mm3; eosinophils if value \>.750 x10\^3 c/uL
| participants | ABA + MTX (Open-Label) |
|---|---|
| Low Hemoglobin (n=458) | 9 |
| Low Hematocrit (n=458) | 5 |
| Low Erythrocyte (n=458) | 8 |
| Low Platelet Count (n=455) | 1 |
| High Platelet Count (n=455) | 1 |
| Low Leukocytes (n=458) | 14 |
| High Leukocytes (n=458) | 12 |
| Low Neutrophils + Bands (absolute) (n=459) | 6 |
| Low Lymphocytes (absolute) (n=459) | 39 |
| High Lymphocytes (absolute) (n=459) | 1 |
| High Monocytes (absolute) (n=459) | 0 |
| High Basophils (absolute) (n=459) | 2 |
| High Eosinophils (absolute) (n=459) | 19 |
Participants with no radiographic progression (defined as change in score \<=0 or \<=0.5), from baseline to Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
| Participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Change from Baseline <= 0 in Erosion Score | 125 | 92 |
| Change from Baseline <= 0.5 in Erosion Score | 144 | 114 |
| Change from Baseline <= 0 in JSN Score | 175 | 150 |
| Change from Baseline <= 0.5 in JSN Score | 190 | 166 |
| Change from Baseline <= 0 in Total Score | 121 | 84 |
| Change from Baseline <= 0.5 in Total Score | 139 | 107 |
Participants with no radiographic progression ((defined as change in score \<=0 or \<=0.5), sustained from Month 12 and Month 24. To assess joint damage progression, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
| Participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Erosion Score Sustained <=0 (n=125; n=100) | 116 | 87 |
| Erosion Score Sustained <=0.5 (n=145; n=114) | 135 | 107 |
| JSN Score Sustained <=0 (n=180; n=165) | 169 | 150 |
| JSN Score Sustained <=0.5 (n=192; n=177) | 185 | 163 |
| Total Score sustained <=0 (n=123; n=97) | 112 | 81 |
| Total Score sustained <=0.5 (n=144; n=112) | 131 | 101 |
Mean difference observed in change from baseline to Month 12 and between Month 12 and Month 24 in radiographic scores (Total Score). To assess joint damage, the Genant-modified Sharp scoring method was used to evaluate radiographs of hands/wrists and feet for erosions and JSN. The total Genant-modified Sharp score ranges from 0 (no radiographic damage) to 290 (worst possible radiographic damage) and is the sum of the erosion score (range 0-145) and the joint space narrowing score (range 0-145). Higher scores indicated more damage.
| units on a scale | Year 1 Change | Year 2 Change |
|---|---|---|
| Mean Difference Observed in Change From Baseline to Month 12 and Between Month 12 and Month 24 in Radiographic Scores (Total Score) | 0.66 ± 0.13 | 0.18 ± 0.13 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Deaths | 2 | 4 |
| SAEs | 20 | 20 |
| Related SAEs | 5 | 6 |
| Discontinued due to SAEs | 3 | 3 |
| AEs | 217 | 211 |
| Related AEs | 98 | 114 |
| Discontinued due to AEs | 8 | 11 |
Number of participants with laboratory values (hematology, liver and kidney functions, electrolytes, glucose tests, protein tests, metabolite tests, and urine chemistry tests) considered markedly abnormal according to prespecified protocol criteria
| participants | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) |
|---|---|---|
| Low Hemoglobin (n=254; n=251) | 3 | 3 |
| Low Hematocrit (n=254; n=250) | 1 | 2 |
| Low Erythrocytes (n=254; n=250) | 1 | 4 |
| Low Platelet Count (n=252; n=250) | 0 | 1 |
| High Platelet Count (n=252; n=250) | 1 | 3 |
| Low Leukocytes (n=254; n=251) | 5 | 11 |
| High Leukocytes (n=254; n=251) | 5 | 14 |
| Low Neutrophils + Bands (absolute) (n=254; n=252) | 2 | 5 |
| Low Lymphocytes (absolute) (n=254; n=252) | 13 | 29 |
| High Lymphocytes (absolute) (n=254; n=252) | 0 | 0 |
| High Monocytes (absolute) (n=254; n=252) | 1 | 1 |
| High Basophils (absolute) (n=254; n=252) | 0 | 0 |
| High Eosinophils (absolute) (n=254; n=252) | 7 | 13 |
| High Alkaline Phosphatase (n=254; n=253) | 1 | 0 |
| High Aspartate Aminotransferase (n=254; n=253) | 7 | 14 |
| High Alanine Aminotransferase (n=254; n=253) | 15 | 21 |
| G-Glutamyl Transferase (n=254; n=253) | 11 | 9 |
| High Bilirubin, Total (n=254; n=253) | 0 | 2 |
| High Blood Urea Nitrogen (n=254; n=253) | 9 | 10 |
| High Creatinine (n=254; n=251) | 33 | 32 |
| Low Sodium, Serum (n=254; n=253) | 0 | 1 |
| High Sodium, Serum (n=254; n=253) | 2 | 0 |
| Low Potassium, Serum (n=254; n=251) | 6 | 3 |
| High Potassium, Serum (n=254; n=251) | 3 | 2 |
| Low Chloride, Serum (n=254; n=253) | 0 | 0 |
| High Chloride, Serum (n=254; n=253) | 1 | 0 |
| Low Calcium, Total (n=254; n=253) | 0 | 0 |
| High Calcium, Total (n=254; n=253) | 0 | 0 |
| Low Phosphorus, Inorganic (n=254; n=251) | 1 | 2 |
| High Phosphorus, Inorganic (n=254; n=251) | 3 | 3 |
| Low Glucose, Serum (n=254; n=253) | 22 | 24 |
| High Glucose, Serum (n=254; n=253) | 10 | 13 |
| Low Protein, Total (n=254; n=253) | 2 | 0 |
| High Protein, Total (n=254; n=253) | 0 | 1 |
| Low Albumin (n=254; n=253) | 2 | 5 |
| High Protein, Urine (n=252; n=250) | 6 | 3 |
| High Glucose, Urine (n=252; n=250) | 4 | 6 |
| High Blood, Urine (n=252; n=250) | 30 | 22 |
| High Leukocyte Esterase (n=87; n=88) | 13 | 13 |
| High Red Blood Cells, Urine (n=92; n=103) | 30 | 25 |
| High White Blood Cells, Urine (n=94; n=105) | 38 | 42 |
| High Uric Acid (n=254; n=253) | 1 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept | — | 20/256 (7.8%) | 150/256 (58.6%) |
| Placebo | — | 20/253 (7.9%) | 155/253 (61.3%) |
| Event | Abatacept | Placebo |
|---|---|---|
| PNEUMONIAInfections and infestations | 1/256 | 3/253 |
| DEPRESSIONPsychiatric disorders | 2/256 | 0/253 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/256 | 1/253 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/256 | 1/253 |
| CHOLECYSTITISHepatobiliary disorders | 0/256 | 1/253 |
| ACUTE HEPATIC FAILUREHepatobiliary disorders | 0/256 | 1/253 |
| ANAPHYLACTIC REACTIONImmune system disorders | 0/256 | 1/253 |
| INTRACRANIAL PRESSURE INCREASEDNervous system disorders | 0/256 | 1/253 |
| ABDOMINAL PAINGastrointestinal disorders | 0/256 | 1/253 |
| GASTROENTERITISInfections and infestations | 1/256 | 1/253 |
| Event | Abatacept | Placebo |
|---|---|---|
| NAUSEAGastrointestinal disorders | 26/256 | 41/253 |
| HEADACHENervous system disorders | 30/256 | 23/253 |
| NASOPHARYNGITISInfections and infestations | 21/256 | 26/253 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 26/256 | 26/253 |
| DIARRHOEAGastrointestinal disorders | 17/256 | 24/253 |
| INFLUENZAInfections and infestations | 19/256 | 23/253 |
| URINARY TRACT INFECTIONInfections and infestations | 17/256 | 22/253 |
| COUGHRespiratory, thoracic and mediastinal disorders | 21/256 | 16/253 |
| DIZZINESSNervous system disorders | 19/256 | 13/253 |
| BRONCHITISInfections and infestations | 18/256 | 12/253 |
| Age Continuous(years) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| Mean | 50.1 ± 12.4 | 49.7 ± 13.0 | 49.9 ± 12.7 |
| Sex: Female, Male(Participants) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| Female | 196 | 199 | 395 |
| Male | 60 | 54 | 114 |
| Anti-Cyclic Citrullinated Peptide 2 (CCP2) Status(participants) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| unknown | 2 | 0 | 2 |
| positive | 236 | 217 | 453 |
| negative | 18 | 36 | 54 |
| Duration of Rheumatoid Arthritis (RA) Disease(participants) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| </= 6 months | 167 | 157 | 324 |
| > 6 months - 12 months | 36 | 34 | 70 |
| > 12 months | 53 | 62 | 115 |
| Rheumatoid Factor (RF) Status(participants) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| unknown | 1 | 1 | 2 |
| positive | 246 | 245 | 491 |
| negative | 9 | 7 | 16 |
| Disease Activity Scale 28 (DAS 28) C-reactive Protein (CRP)(units on a scale) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| Mean | 6.3 ± 1.0 | 6.2 ± 1.0 | 6.3 ± 1.0 |
| Duration of RA(months) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| Mean | 6.2 ± 7.5 | 6.7 ± 7.1 | 6.5 ± 7.3 |
| Erosion Score(units on a scale) | ABA + MTX (Double-Blind) | PLA + MTX (Double-Blind) | Total |
|---|---|---|---|
| Mean | 5.4 ± 6.1 | 4.8 ± 5.4 | 5.1 ± 5.8 |
8 further baseline measures are reported on the registry.
The record gives a start of Jul 2005, a primary completion of Feb 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Methotrexate